Vaxart - VXRT Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1-year price objectives for Vaxart's shares. Their VXRT share price forecasts range from $6.00 to $18.00. On average, they predict the company's share price to reach $10.67 in the next year. This suggests a possible upside of 436.0% from the stock's current price.
View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts.

Vaxart's stock was trading at $6.27 on January 1st, 2022. Since then, VXRT stock has decreased by 68.3% and is now trading at $1.99.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VXRT earnings forecast.

Vaxart, Inc. (NASDAQ:VXRT) announced its quarterly earnings results on Monday, August, 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.02. Vaxart had a negative net margin of 16,892.57% and a negative trailing twelve-month return on equity of 52.93%. During the same quarter in the prior year, the firm earned ($0.13) earnings per share.

Vaxart's stock reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), OrganiGram (OGI) and Novan (NOVN).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Beacon Capital Management LLC (0.01%). Insiders that own company stock include Armistice Capital Master Fund, Armistice Capital, Llc, Fuad Ahmad, John P Richard, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends.

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VXRT stock can currently be purchased for approximately $1.99.

Vaxart (NASDAQ:VXRT) has a market capitalization of $251.75 million and generates $890,000.00 in revenue each year. The biotechnology company earns $-70,470,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

The company employs 110 workers across the globe.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580.